ReviewFrontiers in immunology2026
MicroRNA-based strategies to overcome the immunotherapy barrier in pancreatic ductal adenocarcinoma.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that continues to pose a major clinical challenge, primarily due to the difficulty of early detection and the limited efficacy of existing therapeutic approaches. Immunotherapy, which has revolutionized the treatment of many other cancers, has shown limited success in PDAC, largely because of the complex and immunosuppressive features of its tumor microenvironment (TME). Consequently, strategies aimed at remodeling or modulating the TME have emerged as promising avenues for enhancing the therapeutical potential of immunotherapy in PDAC. MicroRNAs (miRNAs), a class of small non-coding RNAs, have emerged as key regulators of gene expression with multi-target capabilities and relatively low toxicity. Increasing evidence demonstrates that miRNAs play critical roles in regulating immune responses and shaping the TME across diverse tumor types, highlighting their considerable potential in improving immunotherapeutic outcomes in PDAC. In this review, we summarize the functional roles of miRNAs in PDAC and discuss the advantages of miRNA-based therapeutics compared with conventional treatments. We further examine current immunotherapeutic strategies for PDAC and highlight how miRNAs regulate immune activity and TME dynamics, providing mechanistic insights into miRNA-mediated immunotherapy. Finally, we discuss the major challenges limiting clinical translation, including off-target effects, toxicity, and delivery barriers and outline emerging delivery platforms that may enhance therapeutic efficacy. Besides, we explore how emerging technologies, such as artificial intelligence (AI), miniature soft robotics, and advanced 3D imaging ecosystems can be integrated into miRNA-based therapeutic strategies. Together, these innovations may pave the way for more effective, personalized, and patient-centered miRNA-based immunotherapies for PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.